Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Control Eng Pract. 2014 Dec 1;33:161–173. doi: 10.1016/j.conengprac.2014.09.011

Figure 1.

Figure 1

Primary self-report variables associated with naltrexone intervention of fibromyalgia as shown for two representative participants: one participant from the pilot study with placebo-drug (P-D) protocol ((a),(b)) and a participant from the full study with drug-placebo (D-P) protocol ((c),(d)). With the introduction of naltrexone, there is a significant decrease in FM symptoms and increase in sleep quality over time for both participants.